Effect of JAK1/2 inhibition on High-Output Heart Failure Associated With Myeloproliferative Disease

Autor:	Ayaka Endo, Kenji Suzuki, Naoki Hirata, Makoto Takei, Tasuku Hasegawa, Yuki Fujii, Ryuichiro Yagi, Toshiyuki Takahashi, Megumi Kawano, Risa Hayashi
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	medicine.medical_specialty lcsh:Diseases of the circulatory (Cardiovascular) system MPD myeloproliferative disease PH pulmonary hypertension Myeloproliferative disease heart failure RHC right heart catheterization lcsh:RC254-282 pharmacotherapy Pharmacotherapy hemic and lymphatic diseases Internal medicine pulmonary hypertension Medicine Pathological Clinical Case Challenges Multiple myeloma High-output heart failure BNP brain natriuretic peptide treatment business.industry HOHF high-output heart failure medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens VEGF vascular endothelial growth factor Pulmonary hypertension IL interleukin Oncology lcsh:RC666-701 Heart failure Cardiology Cardiology and Cardiovascular Medicine business
Zdroj:	JACC. CardioOncology, Vol 2, Iss 2, Pp 320-323 (2020) JACC: CardioOncology
ISSN:	2666-0873
Popis:	There are reports of some patients with myeloproliferative disease (MPD) developing high-output heart failure (HOHF) ([1][1]). Another hematological disorder, multiple myeloma, is also known to be related to HOHF ([2][2]). According to the common pathological conditions in these 2 hematologic
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fcb13c2c5c4d27d7b7747976ef35c52 http://www.sciencedirect.com/science/article/pii/S2666087320300739 Zobrazit plný text záznamu